Date: 2015-10-10
Type of information: Development agreement
Compound: undisclosed novel small molecule addressing cardiovascular risk in patients with dyslipidemia
Company: Eli Lilly (USA - IN) WuXi PharmaTech (Cayman), a subsidiary of Wuxi Apptec (China)
Therapeutic area: Cardiovascular diseases
Type agreement: development manufacturing production commercialisation
Action mechanism:
Disease: cardiovascular risk in patients with dyslipidemia
Details: * On November 10, 2015, WuXi PharmaTechand Eli Lilly aannounced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China. The potential medicine is a novel, once-daily oral agent, discovered by Lilly, which could address cardiovascular risk in patients with dyslipidemia. This potential medicine aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of cardiovascular events. WuXi will be responsible for regulatory, development and manufacturing activities in China, which will be led and coordinated by WuXi's Product Development Service and Partnership (PDSP) Business Unit. The potential medicine will be manufactured in China by WuXi to support China development. Lilly will be responsible for commercial activities. The parties will both invest in bringing this potential new medicine to patients in China. An Investigational New Drug (IND) application will be filed in China by WuXi, and product development and registration will be carried out within China.
Financial terms: Financial terms of the collaboration were not disclosed.
Latest news:
